This study aimed to identify gene expression markers shared between both influenza hemagglutination inhibition (HAI) and virusneutralization antibody (VNA) responses. We enrolled 158 older subjects who received the 2010-2011 trivalent inactivated influenza vaccine. Influenza-specific HAI and VNA titers and mRNA-sequencing were performed using blood samples obtained at Days 0, 3 and 28 post vaccination. For antibody response at Day 28 versus Day 0, several gene sets were identified as significant in predictive models for HAI (n = 7) and VNA (n = 35) responses. Five gene sets (comprising the genes MAZ, TTF, GSTM, RABGGTA, SMS, CA, IFNG and DOPEY) were in common for both HAI and VNA. For response at Day 28 versus Day 3, many gene sets were identified in predictive models for HAI (n = 13) and VNA (n = 41). Ten gene sets (comprising biologically related genes, such as MAN1B1, POLL, CEBPG, FOXP3, IL12A, TLR3, TLR7 and others) were shared between HAI and VNA. These identified gene sets demonstrated a high degree of network interactions and likelihood for functional relationships. Influenza-specific HAI and VNA responses demonstrated a remarkable degree of similarity. Although unique gene set signatures were identified for each humoral outcome, several gene sets were determined to be in common with both HAI and VNA response to influenza vaccine.
INTRODUCTION
Each year, seasonal influenza infection places a substantial burden on society, both medically and socioeconomically. 1 In the 2014-2015 season alone, nearly 18 000 hospitalizations and 5.0-9.3% of all deaths were directly attributed to influenza infection and related complications, including pneumonia in the United States. 2 Meanwhile, additional research suggests that medical expenses and loss of productivity associated with influenza infection place a financial burden of over $80 billion on the US economy annually. 1 Yearly influenza vaccination is currently the most effective method available to reduce this morbidity and mortality.
Currently, the hemagglutination inhibition (HAI) assay is the most widely accepted measure to assess the protection provided by influenza vaccine. An HAI titer of 1:40 is commonly accepted as a correlate of protection associated with~50% protection against subsequent influenza virus challenge. [3] [4] [5] [6] However, owing to the inability of HAI titers to completely predict susceptibility to future infection, it is clear that HAI antibodies (Abs) provide only a partial explanation of the immunity induced by influenza vaccination. For instance, a recent study noted the ability of patients with little or no HAI Abs to resist influenza infection, suggesting that non-HAI neutralizing activity, such as broader virus neutralization Abs (VNA), may contribute to protection. 7 Interestingly, HAI and VNA titers are often observed to be correlated, although the literature in this area is limited. 8 Another report suggests that VNA titers are a better correlate of protection against influenza infection than HAI titers after immunization with live-attenuated influenza vaccine. 9 Thus, it is important to consider both HAI and VNA titers when determining correlates of protection after influenza immunization.
In order to further explore this issue, it is critical to understand the genomic mechanisms underlying HAI and VNA responses to influenza vaccination. Currently, few biological or genetic markers [10] [11] [12] [13] have been identified that characterize the adaptive immune response to influenza vaccine or predict vaccine failure, and additional research in this area is needed. In this study we used a systems biology approach to explore and identify such potential markers. Our aim for this study was to identify genomic markers (both individual genes and gene sets) in common between both influenza A/H1N1-specific HAI and VNA responses following seasonal trivalent inactivated influenza vaccine (TIV) in older adults. Application of a systems biology approach will advance our knowledge by identifying novel mechanisms and generating hypotheses for variations in adaptive immune responses to vaccines.
RESULTS

Subject demographics
In total, 159 subjects participated in this study 14 and the median (interquartile range) age of the cohort was 59.5 (55.3, 66. 3) years. Female participants represented 61.6% of the cohort, whereas males represented 38.4%. Overall, a majority of the cohort selfidentified as Caucasian (98.7%); the remaining 1.3% reported a race of 'Other.' One subject's sample failed mRNA-sequencing quality control; therefore, data from158 subjects were carried forward for analyses.
vaccination. Day 0 influenza-specific median HAI and VNA titers (median 1:80; interquartile range 1:40-1:320) demonstrated the presence of pre-existing Abs in all subjects. Both HAI and VNA titers increased by Day 28 (1:320; interquartile range 1:160-1:640, Po 0.001 for both outcomes). As expected, we found a strong positive linear relationship between HAI titer and VNA titer for Days 0 (r = 0.924, P = 7.07 × 10 − 67 ), 3 (r = 0.934, P = 1.65 × 10 − 71 ) and 28 (r = 0.940, P = 8.62 × 10 − 75 ), which suggests that Ab responses measured by the HAI and VNA assays are similar ( Figure 1) . The intra-class correlation coefficient was 0.91 for the HAI assay (Day 0) and 0.83 for the VNA assay (Day 0). There were no significant differences in HAI (P = 0.22, P = 0.17 and P = 0.79, for Days 0, 3 and 28, respectively) or VNA (P = 0.37, P = 0.31 and P = 0.41, for Days 0, 3 and 28, respectively) titers between male and female subjects at any timepoint (Figure 2a ). Figure 2b illustrates that there were no significant differences at any time point in HAI (P = 0.56, P = 0.44 and P = 0.15, for Days 0, 3 and 28, respectively) or VNA (P = 0.86, P = 0.51 and P = 0.32, for Days 0, 3 and 28, respectively) responses.
Common gene sets (Log 2 Day 28 vs Day 0) associated with HAI and VNA responses Externally defined gene sets with significant mRNA expression changes from Day 0 to Day 28 (P o0.005) were used in crossvalidated penalized regression models, to predict HAI or VNA change from Day 0 to Day 28 (adaptive immune response). We identified 7 and 35 gene sets containing genes with changes in expression that demonstrated as association with variability in the response and had at least one gene entering the model for the HAI and VNA responses, respectively. In contrast, no gene sets entered the models to predict early HAI or VNA change from Day 0 to Day 3. The genes associated with HAI are RNA transcription factors (TTF2 and MAZ), chemokine/cytokine/receptor (CCR9, IL10RA and IFNG), transferase activity markers (GSTM1, 2, SMS and RABGGTA), carbonic-anhydrases (CA2, 6, 8, 11 and 14) , oxidoreductases (NDUFS3, CYB5R2, 3, CYB561, NQO1 and 2) and the endosome transport dopey family marker (DOPEY2) ( Supplementary Table 1 ). Among gene sets associated with VNA response are tumor necrosis factor ligand TNFSF11, cytokines/ receptors (IFNG, IL7 and IL27), interferon (IFN)-inducible transcription factors (IRF7 and IRF9) and other genes with unknown role in the regulation of humoral immunity (Supplementary Table 2 ). Five gene sets were in common with both HAI and VNA (Table 1) . These genes/gene sets were involved in cellular protein processes (MAZ and TTF2), transferase (GSTM1, GSTM2, RABGGTA and SMS) and carbonate dehydratase (CA2, CA6, CA8, CA11 and CA14) activities, KEGG pathway (IFNG) and endosome transport (DOPEY2).
Common gene sets (Log 2 Day 28 vs Day 3) associated with HAI and VNA responses Using the approach detailed above for gene sets having statistically significant changes between Days 3 (innate immune response) and 28 post influenza immunization, we identified 13 gene sets associated with HAI titers. In addition, 41 gene sets were associated with variation in VNA response to vaccine. Genes in the HAI regression model include endoplasmic reticulum-associated enzyme (MAN1B1), DNA polymerase (POLL) and many other genes with unknown immune function (Supplementary Table 3 ). Genes in the VNA regression model include signal transducers (STAT1 and STAT3), tyrosine kinase (TYK2), Golgi vesicular transport protein (GOSR1) and others. For additional genes and gene sets, see Supplementary Table 4 . Overall, 10 gene sets and related genes were associated with both HAI and VNA responses. Included are immune-related genes MAN1B1, POLL, CEBPG, FOXP3, IL12A, TLR3 and TLR7 ( Table 2 ).
Biologic functions implicated by genes associating with HAI and VNA responses Network interactions among all genes within significant gene sets were extracted, revealing a number of highly interconnected modules. Our statistically prioritized genes were typically representatives from these modules (Supplementary Figure S2 ). Within this network, we calculated the extent of interconnectivity between genes prioritized by our statistical approach ( Figure 3 ) and identified 51% as directly connected to at least one other prioritized gene. Randomly selected gene sets (see Methods) exhibited a mean interconnectivity of 29 ± 4%, indicating a significant level of interrelationships among our prioritized genes; none of the randomly generated sets of genes showed this extent of interconnectivity. Focusing on statistically prioritized genes, many of those associated with both HAI and VNA (including INFG and TLR genes) were found to have known interactions with genes that were uniquely associated with HAI or VNA. Further, a high degree of network interactions were identified between the gene sets prioritized at different time points, indicating a high likelihood for functional relationships between the genes. Thus, the distinct genes/gene sets prioritized for each outcome and time point tend to directly interact with one another, indicating probable participation in common biologic mechanisms.
To add further annotation-based evidence for functional relationships between these genes, we performed Gene Ontology (GO) term enrichment. The most significantly enriched VNAspecific terms were purine salvage and metabolism. The most significantly enriched terms shared by both outcomes are the biosynthetic processes 'long chain fatty-acyl-CoA,' 'positive regulation of IFNG,' and 'triglyceride.' Although many of the statistically enriched terms matched prior expectation (for example, IFNG regulation), 10 some present more novel hypotheses for future study. See Supplementary Figure S1 for the full list of significantly enriched GO terms, by outcome and time point. Abbreviations: HAI, hemagglutination inhibition; MSE, mean squared error; VNA, virus-neutralization antibody. Common gene sets with genes entering regression models for HAI and VNA responses with the log 2 Day 28 versus Day 0 fold-change in gene expression as the explanatory variables. a A positive (+) coefficient from the regression models indicates that as the log 2 fold change for the gene increases from Day 0 to Day 28, then the estimated response increases (upregulated with respect to the change). If the coefficient is negative (− ) as the log 2 fold change for the gene increases, the estimate response decreases. b Cross-validated MSE. Gene sets presented had genes remain in the penalized regression models for both HAI and VNA. The gene set name provides the abbreviation that is used for simplicity in the text, a brief description and gene set name from the MSigDB 64 and the actual gene.
DISCUSSION
The goal of this study was to identify genomic markers in common with both HAI and VNA responses following influenza A/H1N1 vaccination. Although the magnitude of HAI and VNA titers to influenza vaccine are often correlated, as they are in this study (Figure 1 ), the two measures of humoral immunity are different; therefore, it was expected that gene expression models would vary somewhat between the two immune outcomes. Thus, we chose to identify common gene sets/genes based on similarities in HAI and VNA responses.
Through our modeling, we identified five gene sets containing genes with expression changes from Day 0 to Day 28 that demonstrated association with both HAI and VNA titers (Table 1) . Similarly, we identified 10 gene sets containing genes with expression pattern changes from Day 3 to Day 28 ( Table 2) that were associated with variation in both HAI and VNA responses. One of the gene sets associated with both HAI and VNA for Day 28 versus Day 0 expression was CPCD. Genes of particular interest within this gene set include MAZ, a transcription factor, which was prioritized in both models, and TTF2, which is a transcription Abbreviations: HAI, hemagglutination inhibition; MSE, mean squared error; VNA, virus-neutralization antibody. Common gene sets with genes entering regression models for HAI and VNA Responses, with the log 2 Day 28 vs Day 3 fold-change in gene expression as the explanatory variables. a A positive (+) coefficient from the regression models indicates that as the log 2 fold change for the gene increases from Day 3 to Day 28, then the estimated response increases (upregulated with respect to the change). If the coefficient is negative ( − ) as the log 2 fold change for the gene increases, the estimate response decreases. b Cross-validated MSE. Gene sets presented had genes remain in the penalized regression models for both HAI and VNA. The gene set name provides the abbreviation that is used for simplicity in the text, a brief description and gene set name from the MSigDB 64 and the actual gene.
termination factor for RNA polymerase II. 15 Often referred to as Pur1, MAZ encodes for a protein that regulates inflammationinduced expression of serum amyloid A proteins. 16, 17 Data suggest that serum amyloid A is involved in at least two aspects of immune regulation. Serum amyloid A proteins are released from hepatocytes during acute inflammation where they typically collaborate with high-density lipoprotein. 18 This newly formed complex prompts the synthesis of several cytokines and acts as a chemotactic agent for both neutrophils and mast cells. In addition, serum amyloid A is capable of binding to, and activating, TLR4 on B lymphocytes to initiate maturation. 18, 19 We also identified the RA gene set, with significant change between Day 28 versus Day 0. This gene set includes the immune gene IFNG. Studies have shown that IFNγ is capable of inhibiting proliferation of pre-activated B lymphocytes or stimulating activated B-lymphocyte proliferation and isotype switching. 20 Thus, MAZ or IFNG gene expression signature may contribute to differential influenza-specific Ab expression post immunization.
On analysis of changes in gene expression between Day 28 versus Day 3 post influenza vaccination, we identified 10 gene sets associated with both HAI and VNA titers ( Table 2 ). There was one gene in the ERCC gene set (MAN1B1) that entered the regression model. MAN1B1 encodes the enzyme endoplasmic reticulum mannosyl-oligosaccharide 1,2-α-mannosidase (ER mannosidase I, Mnl1). MAN1B1 is commonly referenced in disorders of lysosomal storage 21 due to the enzyme's role in cleaving mannose monomers from newly synthesized peptides within the ER. As Mnl1 is an essential component of quality control for proper protein folding, secretion and function, 22, 23 polymorphisms in MAN1B1 could potentially result in an alteration of the protein profile of immune response to TIV antigens. Recent studies using kifunensine (Mnl1 inhibitor) suggest that Mnl1 affects immune regulation by preventing naive CD4+ T-cell activation, 24 leading to a lack of B-cell co-stimulation and Ab production. Although this phenomenon has been more widely studied for MAN1A1-encoded Mnl1, the observed actions could potentially be generalized to MAN1B1-encoded Mnl1.
When evaluating the change in early-activation gene expression from Day 3 and Day 28 as predictors in the model, the NHEJ gene set had genes enter the regression model for both HAI and VNA. Within this gene set is the POLL gene, which codes for DNA polymerase λ, an enzyme with a critical role in both DNA replication and repair. 25 Previous studies suggest that polymerase λ is involved in DNA base excision repair in the wake of oxidative damage. 26, 27 One study shows that polymerase λ-deficient mice experience a decreased rate of germinal center B-cell receptor somatic hypermutation. 27 This observed decline in somatic hypermutation is thought to be caused by a reduction in the prevalence of B cells due to their inability to successfully repair oxidative DNA damage. It can be proposed that mutations in the POLL gene may affect the ability of germinal center B cells to diversify Ab populations, thereby altering the humoral immune response to influenza.
The immune-associated gene set IFNG also had genes that entered the model for both HAI and VNA when the change in gene expression for Day 28 versus Day 3 was evaluated. Genes of interest in this gene set are FOXP3, INHBA, TLR3 and TLR7; others include CEBPG, EBI3, IL12A and TLR9. However, TLR9 entered models only for the HAI and not for the VNA response.
Studies have shown that FOXP3 serves as the master regulator of T-regulatory cell (Treg) production. Tregs, which are critical for dampening the immune response, have also been shown to secrete cytokines, such as IFNγ, which have important immunoregulatory functions. 28 IFNγ is essential for the induction of FOXP3 in CD4+ T cells. 29, 30 Less research has been conducted on the influence of Tregs on humoral immunity; however, recent studies suggest that Tregs also inhibit B-cell responses to antigens through IFNγ-related mechanisms. It has been suggested that Figure S2) . (c) The network interactions between our statistically prioritized genes demonstrate significant interactions across time points and outcomes. Edges are bundled to increase legibility.
alterations in the ratio of Tregs to T-follicular helper cells within germinal centers exert control over Ab responses. 31 Of further importance in the IFNG gene set is INHBA. This gene encodes the peptide inhibin βA, a subunit of both activin and inhibin; these proteins operate antagonistically within the immune system. 32 Activin A is produced by activated B cells before it directly stimulates naive B cells to increase production of IgG and indirectly stimulates activated B cells to increase IgG and IgE secretion. 33 The Toll-like receptor (TLR) genes, TLR3 and TLR7, also entered the models for both the HAI and VNA response to influenza antigen models when using Day 28 versus Day 3 post vaccination expression. TLRs are well known for their involvement in the innate immune response; however, it has been shown that B cells also express TLRs that, when bound to ligand, enhance cell survival and provoke increased Ab production. 34 Other genes in this gene set include CEBPG, a B-cell transcription factor; 35 EBI3, a gene encoding a subunit of both interleukin (IL)-27 and IL-35; 36 and IL12A, a gene encoding a subunit of the Treg inducer IL-35. 37 We have demonstrated that the genes prioritized by our statistical methods are involved in diverse cellular functions that are important biologically. Our statistical approach filters out genes with highly correlated expression (that is, members of protein complexes or proteins mediating similar biologic functions). Thus, the somewhat diverse set of genes prioritized by our methods are likely to be representatives of broader classes of genes or of specific protein complexes (see Supplementary Figure S2 ).
To interpret the coordinated activity of prioritized genes, we used two types of prior information: network resources and GO term enrichment. These two types of resources provide complementary information: evidence of physical or molecular interactions and participation in the same molecular or biochemical processes, respectively. It is noteworthy that statistically significant GO term enrichment in this context is a descriptive measure about the gene's functions: the genes were prioritized by our statistical approach and we use term enrichment as a means to describe what biologic activities to which they contribute. Through mapping all of the genes identified by our statistical approach onto biologic networks and inspecting the degree of known relationships among them, we find that many share direct interactions. The set of common genes, those prioritized by models of both HAI and VNA, have many direct connections with genes that were prioritized by one outcome, indicating participation in similar functions. This is also true across time points. In order to further identify the functions shared by these genes, we performed GO term enrichment for the entire set and also for each subset (by time point and outcome). Some functions are identified across the individual outcome comparisons, but some are only identified when considering genes across our outcomeassociated results. Specifically, multiple lipid metabolism terms including phosphatidylinositol signaling (including PIP3), lipid (cholesterol, triglyceride and phosphatidylinositol) metabolism and lipid transport are implicated by genes across our comparisons. This broad network-based summary highlights the multifaceted nature of immune response.
Our study design used rigorous randomization approaches in order to minimize the influence of experimental artifacts. Our data reduction steps were agnostic to the outcome being modeled and used externally available immune system knowledge. All modeling involving the outcome was cross-validated to ensure reproducibility. The novelty of this study is evident in that it is the first of its kind to identify gene sets and genes whose changes in expression influence variation in both HAI and VNA responses to influenza A/H1N1 immunization. However, there are limitations to this study. First, the utilization of a larger cohort would enhance statistical power. The examination of gene expression underlying the innate immune response would be beneficial to this study; in order to do this, sample collection on Day 1 post immunization would have been ideal. Lastly, the scope of this study is limited to A/H1N1 influenza and may or may not be generalizable to other components of the TIV.
The unique data and results generated from this study could potentially be used to predict humoral response to influenza vaccine in the future and inform the development of an individualized vaccine schedule paradigm. [38] [39] [40] The identification of gene signatures associated with humoral immunity may provide a better understanding of the genetic markers of immune response and may assist with the design of better vaccines and adjuvants.
MATERIALS AND METHODS
Study subjects
The methodology used for the selection and recruitment of study subjects has been previously reported elsewhere. 14, [41] [42] [43] Briefly, the study included 159 healthy adults, ranging in age from 50 to 74 years old, who were immunized with an intramascular single dose (0.5 ml) of the 2010-2011 seasonal TIV Fluarix (GlaxoSmithKline, Research Triangle Park, NC, USA), containing A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/ Brisbane/60/2008 viral strains. 14, [41] [42] [43] TIV is prepared from split-virion influenza viruses propagated in embryonated chicken eggs and contains a ratio of 15 μg of the hemagglutinin antigen for each of the three influenza strains. 44 Before the onset of the study, each participant provided written, informed consent. All subjects reported stable health and provided detailed vaccination histories. Subjects were excluded from the study if they already received the 2010-2011 TIV. Exclusion criteria included the display of flu-like signs or symptoms at any point throughout the duration of the study. Subjects were also excluded from enrollment if they were diagnosed with influenza, or exhibited symptoms consistent with influenza, at any time from the beginning of the influenza season in Minnesota (as defined by the first reported cases over the period of the individual subject's participation). 45 In addition, one participant was excluded due to cDNA library preparation malfunction. Blood samples (90 ml) from each subject were obtained at three separate time points: prevaccination (Day 0) and Days 3 (innate immune response) and 28 (adaptive immune response) post vaccination. 14 This study was approved by the Mayo Clinic Institutional Review Board.
HAI and VNA assays
We have previously described the HAI and VNA assays. 14, 41, 43 As published elsewhere, [46] [47] [48] the standard WHO protocol 49 was used to determine influenza H1N1-specific (virus strain A/California/07/2009) Ab titers from each subject's serum at all three time points. The HAI titer was defined as the highest dilution of serum that inhibits red blood cell (0.5%) hemagglutination. The VNA titer was defined as the reciprocal of the highest dilution of serum that neutralizes 200 plaque-forming units of influenza A/H1N1 virus.
Seroconversion to influenza vaccine antigens was defined as a fourfold increase in serum Ab titers between Day 0 (before vaccination) and Day 28, or as an increase in serum Ab titers from o10 to ⩾ 40 from Day 0 to Day 28. 50 The average coefficients of variation for the assays performed in this study were 2.9 and 4.7% for HAI and VNA, respectively.
Separation of PBMCs
Methodology used for peripheral blood mononuclear cell (PBMC) preparation is identical to what we have previously published. 42 PBMCs were isolated from blood samples (100 ml) from each subject at each timepoint pre-and post-vaccination using cell preparation tubes with sodium citrate (CPT; BD Biosciences, San Jose, CA, USA), as previously published. 42 Purified PBMCs were resuspended at a concentration of 1 × 10 7 per ml in RPMI-1640 medium containing L-glutamine (Invitrogen; Thermo Fisher Scientific, Carlsbad, CA, USA), supplemented with 10% dimethyl sulfoxide and 20% fetal calf serum (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA). Cells were frozen overnight at − 80°C in freezing containers (Thermo Fisher Scientific) to reach an optimal rate of cooling and then transferred for storage to liquid nitrogen.
mRNA sequencing
To carry out mRNA next-generation sequencing, we used protocols identical to those used and published for our transcriptomic studies. 51, 52 Genetic contributors to influenza antibody response IG Ovsyannikova et al Gene counting was performed using HTSeq (0.5.3p3, EMBL Heidelberg, Germany) and the reads mapping to individual exons were counted using BEDTools (2.7.1, Salt Lake City, UT, USA). [53] [54] [55] Statistical methods
Demographic results are presented as a percent of the total sample for discrete variables or as the median and interquartile range for continuous variables. Spearman's correlation was used to calculate associations between Ab titers. The Wilcoxon rank-sum test was used to test for difference in HAI and VNA titers between male and female subjects, and between subjects who were 50-64 years of age and those who were 65 years and older. Conditional quantile normalization, which adjusts for gene length and GC content, was used to calculate a normalization offset for use in subsequent analyses of the counts from the mRNA-sequencing data. 56 Moderated dispersion estimates were estimated using edgeR, assuming variance was a nonlinear function of the mean, with the tagwise dispersion calculated from the trended dispersion. 57, 58 To identify genes that changed significantly over time, we used generalized linear models, assuming the negative binomial distribution with generalized estimating equations, in order to account for correlation between multiple observations within a subject to obtain per gene P-values. [59] [60] [61] [62] Self-contained gene set tests were performed using the gamma method with soft truncation threshold of 0.15, an extension of Fisher's method of combining per-gene P-values. 63 The gene sets tested were externally defined gene sets from the Molecular Signatures Database 64,65 that were in the Biocarta, GO, KEGG, Reactome, Sigma-Aldrich, Signaling Gateway Signal Transduction KE pathways or had 'virus,' 'infect,' 'pathogen,' or 'innate' as a keyword in the gene set description.
Penalized regression methods were used to build regression models with the goal of understanding the biological processes that may explain variation in vaccine response. 66 Two response variables were evaluated: (1) log 2 fold change of the Day 28 HAI titer relative to the Day 0 HAI titer; and (2) log 2 fold change for Day 28 VNA titer relative to Day 0 VNA titer. Predictor variables were the individual genes from gene sets having statistically significant changes over time (P o0.005, n = 339). Specifically, gene sets with significant changes in Day 28 versus Day 0 and Day 28 versus Day 3 were used in the models (log2 difference in normalized expression between time points). Models were fit to genes from one gene set at a time. The predictor variables were first filtered using redundancy analysis, 67 with an R 2 o0.75 as the cutoff. The remaining genes were included as independent variables in the 'glmnet' function in R, which was used for model selection. 68 Gender was also included as a covariate in the models. Tenfold cross validation was used to select the lambda parameter (based on the minimum cross-validated mean squared error), governing the selection of genes to be incorporated in the final model. The tuning parameter α was set to 0.9, reflective of the elastic net penalty (a combination of the L1 LASSO and L2 ridge penalties). The R statistical software version 3.0.2 was used for all analyses (www.r-project.org).
Genes prioritized by the above statistical models were used in network analysis. In order to be comprehensive and also focus on high-confidence interaction data, multiple network resources were combined including HPRD, 69 CCSB, 70 the Pathway Interaction Database 71 and the subset (7.8%) of STRING, 72 where all interactions had a confidence score of at least 70%. We evaluated the significance level of network connections using random sampling. To do this, we generated a network interconnectivity metric defined as the fraction of genes that are first neighbors of each other, using all statistically significant genes that map to the network (n = 166). We then randomly selected 10 000 sets of the same size from the network, limited to genes that were detected by RNA-Seq in our study (n = 15,708). Network operations were performed using the igraph R package, version 0.7.1. Networks were visualized using Cytoscape 73 version 3.2.1 and layouts refined using AllegroLayout v.2.2.1. 74 The biologic functions of gene sets were evaluated using GO term enrichment. 75, 76 GO terms were extracted from the human GO Annotation database 77 and hypergeometric tests were used to determine enrichment. We reported FDR-corrected P-values (q-values) for terms significant at the qo 0.01 level.
